Virology Overview
A first-pass map for viral structure, specimen timing, NAAT, antigen detection, serology, viral load, genotyping, and public health context.
Core idea
Virology Overview gives students a place to organize the topic before memorizing organism lists, test names, or isolated exam facts.
Principle
Learn this topic by asking what the specimen, method, organism group, and clinical setting are trying to prove. Build the topic around practical study anchors and bench reasoning.
Study Organizer
| Anchor | What to learn first | Why it matters |
|---|---|---|
| Specimen timing | viral shedding and immune response change over time | Use this as a branch point for review, tables, and practice questions. |
| NAAT | detects viral nucleic acid rapidly | Use this as a branch point for review, tables, and practice questions. |
| Serology | detects host response and immunity patterns | Use this as a branch point for review, tables, and practice questions. |
| Viral load/genotyping | monitors disease or resistance in selected infections | Use this as a branch point for review, tables, and practice questions. |
Viral Syndrome-to-Agent Map
| Syndrome lane | Viruses students should place here | Testing habit |
|---|---|---|
| Upper respiratory infection | Rhinovirus/enterovirus, seasonal coronaviruses, adenovirus, influenza, parainfluenza, RSV, metapneumovirus | Respiratory NAAT panels or targeted antigen/NAAT depending on season and setting |
| Croup, bronchiolitis, pneumonia | Parainfluenza, RSV, metapneumovirus, influenza, adenovirus, SARS-CoV-2 and other respiratory viruses | Nasopharyngeal or lower respiratory specimen quality matters |
| Vesicular rash or mucocutaneous lesions | HSV, VZV, enteroviruses in selected syndromes, poxvirus-like differential depending on context | Lesion swab/scraping for NAAT is usually more direct than serology |
| Exanthem or febrile rash | Measles, rubella, parvovirus B19, enteroviruses, HHV-6/7, arboviruses depending on setting | Serology, NAAT, and public health notification depend on syndrome |
| Meningitis/encephalitis | Enteroviruses, HSV, VZV, arboviruses, mumps, measles, JC virus, rabies in selected settings | CSF NAAT is central for many agents; serology helps for some arboviruses |
| Gastroenteritis | Norovirus, rotavirus, enteric adenovirus, astrovirus, sapovirus | Stool antigen/NAAT; routine viral culture is not the modern anchor |
| Hepatitis | HAV, HBV, HCV, HDV, HEV, plus CMV/EBV in selected contexts | Serology and viral load patterns organize acute, chronic, and immune status questions |
| Congenital/perinatal disease | CMV, rubella, HSV, VZV, parvovirus B19, HBV, HIV and others by context | Maternal timing, neonatal specimen, IgM/IgG/NAAT logic, and public health rules matter |
Viral Specimen Selection Map
| Disease question | Best specimen direction | Student warning |
|---|---|---|
| Respiratory virus | Nasopharyngeal swab/aspirate, throat/nasal specimens, or lower respiratory specimen when disease is lower tract | Collection timing and swab type affect NAAT and antigen yield |
| HSV/VZV lesion | Vesicle fluid, lesion base swab, scraping, or tissue depending on site | Older crusted lesions may have lower yield |
| CNS infection | CSF for NAAT and selected serology; serum paired with CSF for some arboviruses | Not every CNS virus is best detected by CSF PCR at every stage |
| Gastroenteritis virus | Stool or rectal swab depending on test validation | Culture is not the routine answer for norovirus/rotavirus-type questions |
| Congenital infection | Neonatal urine, saliva, blood, CSF, tissue, or serology depending on virus | Maternal antibody can complicate interpretation |
| Hepatitis | Serum or plasma for antigen, antibody, and nucleic acid testing | Marker combinations matter more than one isolated result |
| Transplant/reactivation monitoring | Blood/plasma viral load for CMV, EBV, BK, adenovirus or others by protocol | Detection may represent reactivation or asymptomatic replication depending on host and threshold |
Viral Test Type Jobs
| Test type | What it detects | Best use | Common trap |
|---|---|---|---|
| NAAT/PCR | Viral nucleic acid | Rapid diagnosis, low-burden detection, viral load monitoring for selected viruses | Can detect residual or latent/reactivated virus without proving disease alone |
| Antigen detection | Viral protein | Rapid respiratory, stool, or lesion testing depending on assay | Sensitivity varies by timing and specimen quality |
| Serology | Host antibody response | Immunity, recent infection, congenital infection, arboviruses, hepatitis markers | IgM false positives and delayed antibody response can mislead |
| Viral culture | Viable virus able to grow in cells | Selected viruses and legacy/special workflows | Slow and less sensitive than NAAT for many modern questions |
| Cytopathic effect/FA confirmation | Cell culture changes and viral antigen in infected cells | Classic virology identification logic | Many labs no longer rely on culture as first-line testing |
| Viral load | Quantitative nucleic acid level | Monitoring HIV, HBV, HCV, CMV, EBV, BK and selected infections | Numbers must be interpreted by specimen type, assay, and trend |
DNA and RNA Virus Family Organizer
| Family lane | Major human viruses | Core memory anchor |
|---|---|---|
| Adenoviridae | Human adenoviruses | Nonenveloped DNA virus tied to respiratory, eye, GI, urinary, and disseminated disease |
| Herpesviridae | HSV-1/2, VZV, CMV, EBV, HHV-6/7/8 | Enveloped DNA viruses with latency and reactivation |
| Papillomaviridae | Human papillomaviruses | Nonenveloped DNA viruses infecting epithelium; wart and cancer associations |
| Polyomaviridae | BK and JC viruses | Small DNA viruses with kidney/CNS reactivation patterns in immunocompromised hosts |
| Poxviridae | Molluscum contagiosum, orthopoxviruses | Large complex DNA viruses; skin lesions are a major clue |
| Hepadnaviridae | Hepatitis B virus | Partially double-stranded DNA virus with reverse transcription step and chronic infection risk |
| Orthomyxoviridae | Influenza A, B, C | Segmented enveloped RNA viruses; antigenic drift and shift concepts |
| Paramyxoviridae | Measles, mumps, parainfluenza, RSV, metapneumovirus | Enveloped RNA viruses spread mainly by respiratory routes |
| Picornaviridae | Enteroviruses, rhinoviruses, HAV | Small nonenveloped RNA viruses; respiratory, GI, CNS, and hepatitis lanes |
| Caliciviridae | Norovirus and related caliciviruses | Nonenveloped RNA gastroenteritis viruses |
| Coronaviridae | Seasonal coronaviruses and SARS-CoV-2 | Enveloped RNA respiratory/GI virus lane with outbreak potential |
| Flaviviridae | HCV, dengue, yellow fever, West Nile, Zika, Japanese encephalitis and related arboviruses | RNA viruses including hepatitis C and many mosquito/tick-borne agents |
| Togaviridae | Rubella and alphaviruses | Rubella congenital disease plus mosquito-borne encephalitis/arthritis viruses |
| Rhabdoviridae | Rabies virus | Bullet-shaped enveloped RNA virus causing fatal encephalitis without prophylaxis |
| Retroviridae | HIV-1/2, HTLV-1/2 | RNA viruses that reverse transcribe and integrate into host DNA |
| Reoviridae | Rotavirus and Colorado tick fever virus | Segmented double-stranded RNA viruses; rotavirus gastroenteritis is the main student anchor |
| Filoviridae | Ebola and Marburg viruses | Severe viral hemorrhagic fever and high-containment workflow |
| Arenaviridae/Bunyavirales | LCM, Lassa, hantaviruses, many arboviruses | Rodent or arthropod-associated RNA viruses with CNS, hemorrhagic, or pulmonary syndromes |
High-Consequence and Public Health Virus Cues
| Cue | Viruses to consider | Lab action mindset |
|---|---|---|
| Hemorrhagic fever with travel/exposure risk | Ebola, Marburg, Lassa, dengue severe disease, yellow fever, hantaviruses and others by geography | Notify and follow biosafety/public health workflow before routine processing |
| Rabid animal bite or bat exposure | Rabies virus | Postexposure prophylaxis and public health consultation matter urgently |
| Measles-like febrile rash with cough/coryza/conjunctivitis | Measles virus | Airborne precautions and public health testing rules matter |
| Congenital rash/cataract/deafness concern | Rubella virus | Serology/NAAT and public health workflow depend on pregnancy/neonate timing |
| Severe pneumonia outbreak | Influenza, SARS-CoV-2, adenovirus, emerging respiratory viruses | Respiratory NAAT plus infection prevention and outbreak context |
| Meningoencephalitis after mosquito/tick exposure | West Nile, La Crosse, eastern/western equine encephalitis, St. Louis, Powassan and related arboviruses | Serology is often central because CSF PCR can be insensitive after early illness |
Antiviral Agent Study Map
| Virus or syndrome | Drug target idea | Examples students may see | Memory caution |
|---|---|---|---|
| HSV/VZV | Viral DNA polymerase or pyrophosphate-related targets | Acyclovir, valacyclovir, foscarnet | Activation and resistance logic differ by drug |
| CMV | Viral DNA polymerase pathway | Ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir in selected contexts | CMV therapy and monitoring are host- and transplant-context dependent |
| HIV | Reverse transcriptase, integrase, protease, entry/fusion, and maturation targets | NRTIs, NNRTIs, integrase inhibitors, protease inhibitors, entry/fusion inhibitors | Combination therapy and resistance testing matter |
| HBV | Reverse transcription step in HBV replication | Tenofovir, entecavir, lamivudine/adefovir concepts in older tables | HBV DNA trend and chronic infection stage guide interpretation |
| HCV | NS3/4A protease, NS5A, NS5B polymerase targets | Direct-acting antiviral combinations | Older interferon/ribavirin concepts appear in exam history, but current therapy uses DAAs |
| Influenza A/B | Neuraminidase, cap-dependent endonuclease, or M2 uncoating for influenza A only | Oseltamivir, zanamivir, peramivir, baloxavir; amantadine/rimantadine as legacy M2 concepts | Resistance and current guidance matter; M2 drugs are not routine modern anchors |
| RSV | Viral RNA/protein synthesis or passive antibody prevention depending on context | Ribavirin as legacy/special therapy; monoclonal antibody prevention concepts | Most RSV care is supportive; prophylaxis is risk-group specific |
Vaccine and Immune Prophylaxis Anchors
| Prevention type | Examples | Student interpretation |
|---|---|---|
| Live attenuated viral vaccines | MMR, varicella, yellow fever, rotavirus, intranasal influenza in selected settings, older smallpox/vaccinia concepts | Usually strong immune response but avoid in certain immunocompromised or pregnancy contexts |
| Inactivated or non-live vaccines | Inactivated influenza, hepatitis A, rabies, polio IPV and others by schedule | Often safer for immunocompromised hosts but may need boosters |
| Recombinant/subunit/VLP vaccines | HBV, HPV, recombinant zoster and others | Targets specific antigens rather than whole replicating virus |
| Postexposure immune globulin | Rabies, HBV, varicella, measles, hepatitis A in selected settings | Used when exposure risk and immune status make passive protection useful |
| Monoclonal antibody prevention | RSV prevention in high-risk infants/young children depending on current product guidance | This is prevention, not ordinary treatment of established bronchiolitis |
| Travel or outbreak prevention | Yellow fever, hepatitis A, polio, measles, rabies pre-exposure in selected risk groups | Epidemiology and public health guidance decide the product |
Basic workflow
- Define the main question for virology overview.
- Separate screening clues from confirmatory information.
- Connect the topic to specimen quality, method limits, and clinical context.
- Use tables to compare similar organisms, methods, or syndromes.
- Circle back to tools or deep guides only after the core concept is clear.
How to read it
- Specimen timing: viral shedding and immune response change over time
- NAAT: detects viral nucleic acid rapidly
- Serology: detects host response and immunity patterns
- Viral load/genotyping: monitors disease or resistance in selected infections
High-yield trapCommon mistakes
- Memorizing names without knowing the organizing branch.
- Forgetting specimen source and patient context.
- Treating a screening clue as a final answer.
ShortcutStudent shortcut
For virology overview, learn the organizer first, then add exceptions.